Literature DB >> 28601867

Novel Insights into the Direct Removal of Endotoxin by Polymyxin B Hemoperfusion.

Alexander D Romaschin1, Christina V Obiezu-Forster, Hisataka Shoji, David J Klein.   

Abstract

AIM: To demonstrate the capacity of polymyxin B-direct hemoperfusion (PMX-DHP) column Toraymyxin® 20R (PMX-20R) in removing endotoxin (LPS) from perfused blood, serum and plasma.
METHODS: Endotoxin-spiked bovine serum was perfused in PMX-20R as per the recommended performance testing protocol. Samples were taken at various time points to assess the amount of endotoxin removed during a 4-h session. In another set of experiments, FITC-labelled LPS (FITC-LPS) was spiked into a pool of human whole blood, followed by perfusion with the spiked blood for 2 h in order to allow FITC-LPS to bind PMX-20R. The amount of LPS was extracted from the columns and the amount of specifically bound LPS was determined by fluorometry.
RESULTS: PMX-20R columns perfused with bovine serum had an average binding rate of 88%, equivalent to approximately 12 µg of LPS. When PMX-20R was perfused with human whole blood, the columns bound an average of 20 µg of FITC-LPS.
CONCLUSION: PMX-20R can bind LPS in all the biological fluids tested. The calculated binding capacity of 12-20 µg LPS suggests that in septic cases where endotoxin is present in the circulation, PMX-20R is able to adsorb clinically significant levels of endotoxin.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Endotoxin activity assay; Hemoperfusion; LPS/endotoxin adsorption; Polymyxin B-direct hemoperfusion; Sepsis; Toraymyxin® 20R

Mesh:

Substances:

Year:  2017        PMID: 28601867     DOI: 10.1159/000475982

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  8 in total

1.  Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.

Authors:  R Phillip Dellinger; Sean M Bagshaw; Massimo Antonelli; Debra M Foster; David J Klein; John C Marshall; Paul M Palevsky; Lawrence S Weisberg; Christa A Schorr; Stephen Trzeciak; Paul M Walker
Journal:  JAMA       Date:  2018-10-09       Impact factor: 56.272

2.  PolyBall: A new adsorbent for the efficient removal of endotoxin from biopharmaceuticals.

Authors:  Sidharth Razdan; Jee-Ching Wang; Sutapa Barua
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

3.  Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study.

Authors:  Won Young Lee; Hee Ju Kim; Eun Young Kim
Journal:  Sci Rep       Date:  2021-12-16       Impact factor: 4.379

Review 4.  The Rationale and Current Status of Endotoxin Adsorption in the Treatment of Septic Shock.

Authors:  Jakub Śmiechowicz
Journal:  J Clin Med       Date:  2022-01-26       Impact factor: 4.241

Review 5.  Immune Modulation in Critically Ill Septic Patients.

Authors:  Salvatore Lucio Cutuli; Simone Carelli; Domenico Luca Grieco; Gennaro De Pascale
Journal:  Medicina (Kaunas)       Date:  2021-05-31       Impact factor: 2.430

6.  In vitro comparison of the adsorption of inflammatory mediators by blood purification devices.

Authors:  Benjamin Malard; Corine Lambert; John A Kellum
Journal:  Intensive Care Med Exp       Date:  2018-05-04

7.  The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients.

Authors:  Nattachai Srisawat; Somkanya Tungsanga; Nuttha Lumlertgul; Chalermchai Komaenthammasophon; Sadudee Peerapornratana; Nicha Thamrongsat; Khajohn Tiranathanagul; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Kriang Tungsanga; John A Kellum
Journal:  Crit Care       Date:  2018-10-26       Impact factor: 9.097

8.  Importance of Endotoxin Clearance in Endotoxemic Septic Shock: An Analysis From the Evaluating Use of PolymyxinB Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemic Septic Shock (EUPHRATES) Trial.

Authors:  Jean-Sebastien Rachoin; Debra Foster; River Giese; Lawrence S Weisberg; David J Klein
Journal:  Crit Care Explor       Date:  2020-02-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.